This disclosure relates generally to cardiac treatment devices and techniques, and in particular, to methods and devices for repair of mitral valve defects such as mitral valve regurgitation.
The mitral valve is one of four heart valves that direct blood through the two sides of the heart. The mitral valve itself consists of two leaflets, an anterior leaflet and a posterior leaflet, each of which are passive in that the leaflets open and close in response to pressure placed on the leaflets by the pumping of the heart.
Among the problems that can develop or occur with respect to the mitral valve is mitral valve regurgitation (MR), in which the mitral valve leaflets become unable to close properly, thus causing leakage of the mitral valve. Severe mitral regurgitation is a serious problem that, if left untreated, can adversely affect cardiac function and thus compromise a patient's quality of life and life span.
Currently, mitral regurgitation is diagnosed by many indicators, and the mechanism of mitral regurgitation can be accurately visualized by trans-esophageal echocardiography or fluoroscopy with dye injection. The most prevalent and widely accepted current technique to correct mitral regurgitation is to repair the mitral valve via open-heart surgery while a patient's heart is stopped and the patient is on cardiopulmonary bypass, a highly invasive procedure that has inherent risks.
In one aspect, a method is described comprising inserting an implant proximate a mitral valve, the implant comprising a tubular body and a plurality of piercing members, the tubular body comprising an upper (i.e. proximal) diameter and a lower (i.e. distal) diameter. The method also includes engaging tissue proximate the mitral valve by the plurality of piercing members and transitioning the tubular body from a first structural configuration to a second structural configuration by application of an expansive force to the tubular body proximate the upper diameter, the first structural configuration having the upper diameter smaller than the lower diameter and the second structural configuration having the upper diameter larger than the lower diameter.
In another aspect, an implant is described comprising a tubular body comprising an upper diameter and a lower diameter, the tubular body having a first structural configuration in which the upper diameter is smaller than the lower diameter and a second structural configuration in which the upper diameter is larger than the lower diameter, the tubular body configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the upper diameter. The implant also comprises a plurality of piercing members connected to the tubular body and proximate the lower diameter to engage tissue proximate a mitral valve.
In another aspect, a system is described comprising a guide wire, a sheath over the guide wire, and an implant for delivery to a body by traveling through the sheath and along the guide wire. The implant comprises a tubular body comprising an upper diameter and a lower diameter, the tubular body having a first structural configuration in which the upper diameter is smaller than the lower diameter and a second structural configuration in which the upper diameter is larger than the lower diameter, the tubular body configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the upper diameter. The implant also comprises a plurality of barbs connected to the tubular body and proximate the lower diameter to penetrate tissue proximate a mitral valve.
In another aspect, a delivery system for delivering an implant within the heart for reducing the size of a heart valve annulus is described. The delivery system comprises a plurality of rotatable drivers and the implant. The plurality of rotatable drivers is configured to extend through one or more lumens of the delivery system. The implant is configured for delivery within the heart by traveling through the one or more lumens of the delivery system. The implant comprises a tubular body and a plurality of helical anchors. The tubular body comprises a frame defining a proximal diameter and a distal diameter. The tubular body has a first structural configuration in which the proximal diameter is smaller than the distal diameter and a second structural configuration in which the proximal diameter is larger than the distal diameter. The plurality of helical anchors are connected to the tubular body proximate the distal diameter of the frame. The plurality of helical anchors are configured to be rotated by the rotatable driver to advance the plurality of helical anchors distally relative to the frame and penetrate the heart valve annulus.
In some embodiments of the delivery system, the implant may further comprise a series of distal apices and a series of holes. The series of distal apices may be formed by the frame proximate the distal diameter. The series of holes may be in each of the distal apices and are sized and spaced to receive therethrough a corresponding helical anchor for rotational engagement of the distal apex by the corresponding helical anchor. The plurality of rotatable drivers and the implant may be configured for transcatheter delivery of the implant to the heart. The delivery system may further comprise a delivery catheter comprising the one or more lumens of the delivery system. A distal end of the delivery catheter may be configured to advance through an opening in the femoral vein, through the femoral vein and into the right atrium of the heart, and through the septum of the heart into the left atrium. The delivery system may further comprise a location ring configured to be located on a side of the heart valve opposite the implant and to couple with the implant. The location ring may be separate from the implant and configured to be located on a side of the heart valve opposite the implant to assist in positioning the implant. The location ring may be configured to be removed from the heart after the implant is positioned and the plurality of helical anchors penetrate the heart valve annulus. The delivery system may comprise one lumen configured to receive therethrough an intracardiac echo catheter for visualizing a position of the implant relative to the mitral valve annulus. The delivery system may further comprise the intracardiac echo catheter. The implant may further comprise an expandable tubular member coupled with a proximal end of the frame and configured to expand to increase the proximal diameter of the frame. The expandable tubular member may be integral with the frame.
In another aspect, an implant for reducing the size of a heart valve annulus is described. The implant comprises a tubular body and a plurality of helical anchors. The tubular body comprises a frame defining a proximal diameter and a distal diameter. The tubular body has a first structural configuration in which the proximal diameter is smaller than the distal diameter and a second structural configuration in which the proximal diameter is larger than the distal diameter. The plurality of helical anchors are connected to the tubular body proximate the distal diameter of the frame. Each of the plurality of helical anchors is configured to be rotated by a plurality of rotatable drivers through a series of holes in lower apices of the frame to advance the plurality of helical anchors distally relative to the frame and penetrate the heart valve annulus.
In some embodiments, the implant further comprises an expandable tubular member proximate a proximal end of the frame, wherein when force is applied to the expandable member, the expandable member expands and engages the proximal end of the frame causing the frame to invert from the first structural configuration to the second structural configuration. The expandable tubular member may be integral with the proximal end of the frame. The expandable tubular member may be a stent-like member positioned internally of the frame proximate the proximal diameter of the frame. The implant may be configured to be contracted to a delivery configuration for transcatheter delivery of the implant to the heart by a delivery system. The implant may further comprise an expandable tubular member coupled with a proximal end of the frame, wherein contracting the expandable tubular member for transcatheter delivery causes the proximal diameter of the frame to decrease relative to an unconstrained state, which causes the distal diameter of the frame to increase relative to the unconstrained state such that the proximal and distal diameters of the frame are approximately the same when delivered. The implant may further comprise angled segments of the frame forming distal apices of the frame proximate the distal diameter, and the series of holes in each of the distal apices may be sized and spaced to receive therethrough a corresponding helical anchor for rotational engagement of the distal apex by the corresponding helical anchor. The tubular body may be configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the proximal diameter.
For a more complete understanding of the present disclosure and its features and advantages, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:
The present disclosure relates to an implant including a tubular body and piercing members for reshaping a mitral valve suffering from mitral regurgitation. The implant may include two or more structural configurations. In a first structural configuration, an upper, i.e. proximal, diameter (away from the mitral valve) may be smaller than a lower, i.e. distal, diameter (proximate the mitral valve). In this first structural configuration, the piercing members of the implant may engage the tissue proximate the mitral valve, for example, the mitral valve annulus. The implant may then be transitioned from the first structural configuration to a second structural configuration in which the size of the upper diameter is larger than the lower diameter. This may be facilitated by an expansive force causing the upper diameter to expand, in turn causing the lower diameter to contract. As the lower diameter contracts, the penetrating members engaged with the tissue proximate the mitral valve may cause the mitral valve to also contract to a smaller diameter. This may allow the valve leaflets to close properly, addressing mitral regurgitation.
In one embodiment of the present disclosure, catheter 140 may include an extendable guide wire assembly 160, which may guide the system into position. Guide wire 160 may measure between 0.010 inches and 0.038 inches in diameter, and may be 0.035 inches in diameter. Catheter 140 or sheath 150 when accessed through the apex of the heart may measure about twenty to thirty centimeters in length.
As shown in
Implant 110 may include a tubular body with portions of the tube removed similar to a stent structure where a portion of the material may be removed via laser cutting or other means to selectively cut portions of the tube away forming a radially-expandable tubular body.
Implant 110 may be introduced in a collapsed structural configuration. This collapsed structural configuration may allow implant 110 to fit within sheath 150 to allow for a percutaneous procedure rather than an open-heart procedure. As shown in
In some embodiments, implant 110 may be tapered such that one end may be larger in diameter than the other end, appearing generally frustoconical in shape. The diameters of the ends may be approximately twenty five millimeters on the smaller end and approximately thirty five millimeters on the larger end. Implant 110 may also be non-circular where a portion of the implant may be elliptical or include a radial portion that is flat. This flat portion may be oriented toward the aortic valve and the circular portion may be positioned toward the posterior leaflet. To facilitate discussion of implant 110, an upper portion and lower portion may be described. The lower portion may refer to the end of implant 110 proximate mitral valve 170 while the upper portion may refer to the end of implant 110 free in the left atrium.
Implant 110 may include piercing members 115 proximate the lower portion of implant 110 proximate mitral valve 170 to engage with tissue proximate mitral valve 170, for example, the mitral valve annulus. Piercing members 115 may include barbs or hooks similar to fish hook barbs or other similar feature to resist withdrawal from tissue once pierced. Piercing members 115, barbs or hooks of the piercing members 115, or any combination thereof may pierce the tissue to engage with the tissue. Piercing members 115 may include a singular barb or hook, or a plurality of barbs or hooks per piercing member 115. Piercing members 115 may be immediately exposed or covered for delivery. They may number from one to fifty and may have a length of about four to twenty millimeters in length. They may have the same wall thickness as a wall of the tubular body of implant 110 or may differ with an increased or decreased thickness or taper in either direction to allow for mechanical integrity.
Piercing members 115 of implant 110 may be integral or attached to implant 110 as a secondary component glued, welded, or attached as an ancillary part. Piercing members 115 may also be laser cut into implant 110, and therefore attached to implant 110. The barbs or hooks may be fatigue resistant from fracture or separation from piercing members 115. For example, the barbs or hooks may have additional strength or wall thickness at the connection to piercing members 115. The barbs or hooks may also be attached with a hinged attachment allowing motion relative to the heart, but not longitudinally where the barbs or hooks may separate from piercing member 115.
The barbs or hooks of piercing member 115 may be active or passive meaning that the barbs or hooks may be activated with heat to bend or expose or mechanically formed through an external force to bend or expose. For example, each barb or hook may be sheathed inside a tube and removal of this tube may allow the barb or hook to be activated by, for example, body heat or some other activation factor, such that the barb or hook is exposed so as to engage the surrounding tissue. In a passive configuration, the barbs or hooks may be static in nature and either always exposed or exposed as soon as a covering is removed. The barbs or hooks may be hidden until deployment limiting the exposure during delivery and positioning and only exposed once positioning is finalized. The exposure may be completed as individual barbs or as multiples of barbs. In some embodiments, the covering is thus only a temporary covering.
As shown in
As shown in
As shown in
In some embodiments, location ring 120 may also act as an anchor for implant 110. In such an embodiment, implant 110 above mitral valve 170 (i.e. in the left atrium side of mitral valve 170) may attach to location ring 120 below mitral valve 170 (i.e. in the left ventricle side of mitral valve 170). For example, the hooks or barbs of piercing members 115 may engage with location ring 120. This may be accomplished by a through suture, a barbed means, wrapping or clipping location ring 120 to implant 110. Magnetic forces may also hold location ring 120 and implant 110 together either temporarily or permanently. Alternatively, the hooks or barbs may also be attached to some other separate implant below mitral valve 170 in the left ventricle. This may be a wire, ring, or tee anchor to secure implant 110 to via wires, threads or mechanical means to attach through the tissue median. For convenience, this implant below mitral valve 170 may be referred to as location ring 120, even if not used in locating implant 110 proximate mitral valve 170.
In some embodiments, the shape of location ring 120 may be a circular cross section measuring about 0.010 inches to about 0.090 inches in diameter and may encircle the mitral annulus. The shape may also be non-circular, oval, biased to one axis or multi-axis to accommodate the multi-plane shape of mitral valve 170, which is more saddle shaped. It may also have a variable stiffness in different sections to accommodate tighter bends in the placement of location ring 120. Location ring 120 and or a delivery catheter may also be steerable to navigate the area under mitral valve 170 for ease of placement. Utilizing push pull wires to compress or load portions of the catheter or location ring 120 to predictably bend and orient the catheter or location ring 120 may allow a user to access difficult anatomical features en route to and around mitral valve 170.
As shown in
As shown in
The construction of implant 110 may include a tapered laser cut tube expanded to a predetermined diameter with wall thickness approximately 0.005 inches to approximately 0.050 inches and a strut thickness of approximately 0.010 inches to approximately 0.070 inches and an expanded diameter of approximately 1.00 inch. If the implant is tapered, the large diameter may measure about thirty five millimeters in diameter and the smaller diameter may measure about twenty five millimeters in diameter. In the first structural configuration, the lower portion (i.e. the larger diameter section) may have penetrating members 115 to engage the mitral annulus and hold implant 110 in position during annuls reduction and remain as a permanent implant.
As shown in
As shown in
As shown in
In some embodiments, a fixed ring 320 may be utilized. Fixed ring 320 may be moved vertically to expand the upper portion to increase upper, i.e. proximal, diameter 330, thus causing the lower portion to reduce lower, i.e. distal, diameter 340 along with the engaged tissue and mitral valve. For example, upward force “D” may be applied to ring 320. However, because of the frustoconical shape of implant 310, the upward force “D” may be translated to an expansive lateral force causing an increase in upper diameter 330. Ring 320 may lock into implant 310 by an interference fit or a mechanical stop built in ring 320 or implant 310, and may maintain implant 310 in the second structural configuration. In some embodiments, the fixed ring 320 may have a smaller diameter and initially be located at or near the upper diameter 330, thus restraining the upper diameter 330 and causing and/or maintaining the first structural configuration of the implant 310 shown in
Alternatively, an expandable ring 320 may be used rather than a fixed ring. Expandable ring 320 may be positioned within implant 310 and may be delivered and expanded by a catheter, for example using hydraulic or mechanical force to expand ring 320. Ring 320 may be introduced into implant 310's inner diameter where ring 320 may be tilted to allow for manipulation or positioning. Alternatively, ring 320 may be placed at a defined vertical position in implant 310 and ring 320 may be expanded, for example with mechanical or hydraulic force or an extension of the radial dimension. Ring 320 may also serve as a locking mechanism for implant 310 once the second structural configuration or the final position has been reached. The expansion and/or locking of ring 320 may be reversible in nature, thus undoing the expansion of the upper portion. Ring 320 may lock into implant 310, for example by an interference fit or a mechanical stop built in ring 320 and/or implant 310.
Support beams 420A and 420B may be integrally formed with implant 410, for example, as a thicker portion of a wall of the tubular body of implant 410, or a specific alignment of repeating units or elements of the structure of the wall of the tubular body. Alternatively, support beams 420A and 420B may be an additional support component added to implant 410. For example, they may be glued, welded, or otherwise permanently affixed to implant 410.
As shown in
As shown in
As shown in
As shown in
Radio frequency (RF) is a rate of oscillation in the range of about three kHz to three hundred GHz, which corresponds to the frequency of radio waves, and the alternating currents, which carry radio signals. RF usually refers to electrical rather than mechanical oscillations. Below is a chart of common nomenclature for different frequency ranges. The range utilized for barb penetration may be somewhere between ELF and HF as the goal is small vibration and not heating of the tissue. Possible user range selection would allow for different tissue types and densities.
Vibration to enhance tissue penetration by the anchor may be delivered from a vibration source to tissue adjacent the penetration site, such as by the vibration pads discussed above. The vibration source may be embedded in the pad or other vibration interface at the distal end of an elongate control element such as a wire or tube. Alternatively, the vibration source may be located in a proximal manifold and propagate vibrational energy distally through an elongate wire or tube extending through the catheter body. The vibration source can alternatively be coupled in vibration propagating communication with either the implant frame or with each individual anchor directly, such as through the anchor driver, depending upon desired performance.
Anchors 930 may be metallic helical members. The anchors 930 may threadingly engage with the lower, i.e. distal, apices of frame 920. The anchors 930 may wind through a series of holes through holes drilled in the distal ends or distal apices of frame 920 (more clearly indicated by reference numerals 1050 in
The implant 910 may include the expandable portion or member 940. The expandable member 940 may be stent-like. The expandable member 940 may be tubular with a wall circumferentially defining a central axis. The expandable member 940 may include angled segments as shown, and/or other segments, configurations, etc. While shown in the shape of a sinusoid, the expandable member 940 may otherwise have a diamond lattice or hexagonal lattice architecture, for example. The expandable member 940 may be a dissimilar material as that of the frame 920. The expandable member 940 may be made of metallic alloys such as stainless steel, cobalt chromium, platinum iridium and the like. The expandable member 940 may be collapsed or crimped for insertion into a delivery system and forcibly expanded, so as to undergo plastic deformation, to invert the frame 920. As shown in
Implant 910 is loaded into the distal end of a delivery system (not shown), by compressing or collapsing the frame 920. Anchors 930 would be initially retracted for loading and delivery. Once positioned in a desired location proximate the mitral valve annulus, frame 920 is advanced out of the delivery system and its distal apices are abutted to the target heart tissue for anchor placement. The helical anchors are then advance, by rotation thereof, into the target cardiac tissue thereby anchoring implant 910 into the region of the mitral valve annulus. Implant 910 is then fully released from the delivery system.
After implant 910 is fully released from the delivery system, expandable member 940 is then forcibly expanded, such as by a dilatation balloon, causing frame 920 to invert. Inversion of frame 920 causes the anchor bearing distal end of frame 920 to taper or contract, causing the mitral valve annulus to reduce in size thus limiting the mitral valve regurgitation.
To perform the procedure of influencing the size of the mitral annulus, for example for treating the patient's mitral regurgitation, the expandable member 940 and the larger, proximal end of frame 922 are compressed or crimped and loaded into the distal end of a delivery system (not shown). This action also causes the distal or narrower end of frame 930 to invert. Such inversion must be restrained for loading into the delivery system.
Once positioned in the desired location proximate the heart valve annulus, such as the mitral valve annulus, the frame 922 is advanced out from the distal end of the delivery system, inverting as it is no longer constrained by the delivery system and expandable member 940 remains in the crimped configuration. The distal ends or distal apices of frame 922 are then positioned in abutting relationship to the target cardiac tissue proximate the mitral valve annulus. Helical piercing members 930 are then rotationally advanced into and in engagement with the target heart tissue in a manner very similar to the helical screw of a corkscrew advancing through a cork. The expandable member 940 is then expelled from the delivery system and forcibly expanded, for example by dilatation balloon which balloon could be an integral component of the delivery system. Expansion of the stent-like expandable member 940 causes frame 922 to revert to its nominal or free state thereby causing its distal apices and helical anchors to become narrower in diameter reducing the size of the mitral annulus and limiting the degree or extent of mitral regurgitation.
Delivery of implant 1010 may be conducted in similar respect to the embodiment of
After implant 1010 is fully released from the delivery system, expandable member 1040 is then forcibly expanded, such as by a dilatation balloon, causing frame 1020 to invert as shown in
The delivery system 950 may include a tube or tube-like structure having one or more lumens extending therethrough. For instance, the delivery system 950 may include an elongated tube or delivery catheter having one or more openings, i.e. lumens, extending therethrough and configured to receive therein, or having therein, corresponding features of the delivery system 950, including but not limited to the guide wire 160, the catheter 140, one or more of the drivers 952, and the intracardiac echo catheter 960. In some embodiments, the delivery system 950 includes a delivery catheter having a lumen to guide the delivery catheter over the guide wire, another lumen or lumens that include(s) the rotatable drivers 952, the implant 912 in a constrained delivery configuration located at a distal end of the delivery catheter, and a sheath covering the distal end of the catheter. Delivery system 950 is advanced transfemorally, either through the femoral vein and transeptally to the left atrium or through the femoral artery up through the aortic arch and then passed the aortic and mitral valves into the left atrium. Once positioned above mitral annulus and proximate the target heart tissue, the implant is partially released, releasing the frame portion 920, 1020. Frame 920, 1020 is now unconstrained and able to return to its nominal or free state as shown in
Helical piercing members 930 are then rotationally advanced into the target cardiac tissue, anchoring the implant to the interior heart wall above the mitral annulus. The implant and expandable member 940, 1040 is then released from delivery system 950. At such time, the stent like member 940, 1040 is forcibly expanded causing the frame 920, 1020 to invert. The distal end of apices and helical anchors 930 are then cinched inwardly reducing the diameter of the distal end of frame 920, 1020 causing a corresponding reduction in the size of the mitral annulus. This reduction in size of the mitral annulus, allows the mitral valve leaflets to better, if not completely, coapt reducing the severity of the patient's mitral regurgitation.
In a further embodiment of the present invention, an intracardiac echo catheter 960 is incorporated in delivery system 950. Catheter 960 could be included in a lumen of delivery system 950, either internally as shown, or alongside implant delivery system 950. By rotating catheter 960 within the left atrium and proximate the mitral valve annulus, the relative position of the implant with respect to the mitral valve leaflets can be determined. This allows for accurate positioning of helical anchors 930 into the target heart tissue proximate the mitral annulus without piercing the mitral valve leaflets.
As shown in
The drivers 952, only some of which are labelled for clarity, are each engaged with a corresponding rotational anchor 930. The drivers 952 may be pre-engaged with the anchors 930 within the delivery catheter of the delivery system 950 before insertion of the distal end of the delivery system 950 into the atrium. The drivers 962 may be mechanically engaged with the anchors 930 in a variety of suitable approaches. For example, the drivers 962 may have a clevis type fitting as shown configured to surround the proximal end of the anchors 930. The drivers 952 may extend over, on, under, etc. the proximal ends of the anchors 930 and then be rotated to transmit rotation to the anchors 930. In some embodiments, the anchors 930 may have recesses or other tool-receiving portions engaged by the drivers 952 such that rotation of the drivers 952 is transmitted to the anchors 930. In some embodiments, the drivers 952 may include socket type fittings that surround the anchors 930. In some embodiments, the anchors 930 may have internally-threaded blind holes through which corresponding externally-threaded members of the drivers 952 are received. These are merely some examples of how the drivers 952 may be engaged with the anchors 930, and other suitable approaches may be implemented. With the implant 910 in position for anchoring to the annulus, a proximal end of the drivers 962 may be manipulated by the user, for example rotated by the surgeon, to rotate the anchors 930 and thereby advance the anchors 930 into heart tissue, as described herein, to secure the implant 910 with the heart tissue. Each driver 952 may be actuated simultaneously, some may be actuated simultaneously, or they may be actuated sequentially. The anchors 930 may extend distally relative to the frame, as described herein.
As shown in
Though a particular path of transcatheter delivery is described with respect to
This disclosure encompasses all changes, substitutions, variations, alterations, and modifications to the example embodiments herein that a person having ordinary skill in the art would comprehend. Similarly, where appropriate, the appended claims encompass all changes, substitutions, variations, alterations, and modifications to the example embodiments herein that a person having ordinary skill in the art would comprehend. Moreover, reference in the appended claims to an apparatus or system or a component of an apparatus or system being adapted to, arranged to, capable of, configured to, enabled to, operable to, or operative to perform a particular function encompasses that apparatus, system, component, whether or not it or that particular function is activated, turned on, or unlocked, as long as that apparatus, system, or component is so adapted, arranged, capable, configured, enabled, operable, or operative. For example, various embodiments may perform all, some, or none of the steps described above. Various embodiments may also perform the functions described in various orders.
Although the present disclosure has been described above in connection with several embodiments; changes, substitutions, variations, alterations, transformations, and modifications may be suggested to one skilled in the art, and it is intended that the present disclosure encompass such changes, substitutions, variations, alterations, transformations, and modifications as fall within the spirit and scope of the appended claims.
This application is a continuation of Ser. No. 17/081,128, filed Oct. 27, 2020, which is a continuation of Ser. No. 15/423,374, filed Feb. 2, 2017, which claims the benefit of priority to U.S. Provisional Application No. 62/291,347, filed on Feb. 4, 2016, and which is a Continuation-in-Part Applications of U.S. application Ser. No. 14/427,909, filed on Mar. 12, 2015, which is a U.S. National Phase Application of PCT International Application No. PCT/US2013/059751, filed on Sep. 13, 2013, designating the United States of America and published in the English language, which is an International Application of and claims the benefit of priority to U.S. Provisional Application No. 61/700,989, filed on Sep. 14, 2012. Each of the above-referenced applications are hereby expressly incorporated by reference herein in their entireties for all purposes and form a part of this specification. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 C.F.R. § 1.57.
Number | Name | Date | Kind |
---|---|---|---|
3143742 | Cromie | Aug 1964 | A |
4042979 | Angell | Aug 1977 | A |
4290151 | Massana | Sep 1981 | A |
4602911 | Ahmadi et al. | Jul 1986 | A |
4820299 | Philippe et al. | Apr 1989 | A |
5064431 | Gilbertson et al. | Nov 1991 | A |
5254127 | Wholey et al. | Oct 1993 | A |
5370685 | Stevens | Dec 1994 | A |
5674279 | Wright et al. | Oct 1997 | A |
5674280 | Davidson et al. | Oct 1997 | A |
5769816 | Barbut et al. | Jun 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5810882 | Bolduc et al. | Sep 1998 | A |
5824066 | Gross | Oct 1998 | A |
5968053 | Revelas | Oct 1999 | A |
5984959 | Robertson et al. | Nov 1999 | A |
6001127 | Schoon et al. | Dec 1999 | A |
6059731 | Seward et al. | May 2000 | A |
6074418 | Buchanan et al. | Jun 2000 | A |
6176877 | Buchanan et al. | Jan 2001 | B1 |
6210432 | Solem et al. | Apr 2001 | B1 |
6254642 | Taylor | Jul 2001 | B1 |
6355030 | Aldrich et al. | Mar 2002 | B1 |
6402780 | Williamson, IV et al. | Jun 2002 | B2 |
6582460 | Cryer | Jun 2003 | B1 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6652537 | Mercereau et al. | Nov 2003 | B2 |
6676692 | Rabkin et al. | Jan 2004 | B2 |
6695878 | McGuckin, Jr. et al. | Feb 2004 | B2 |
6702826 | Liddicoat | Mar 2004 | B2 |
6726716 | Marquez | Apr 2004 | B2 |
6730121 | Ortiz et al. | May 2004 | B2 |
6743239 | Kuehn et al. | Jun 2004 | B1 |
6776791 | Stallings et al. | Aug 2004 | B1 |
6786925 | Schoon et al. | Sep 2004 | B1 |
6790231 | Liddicoat et al. | Sep 2004 | B2 |
6805710 | Bolling et al. | Oct 2004 | B2 |
6824562 | Mathis et al. | Nov 2004 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6913608 | Liddicoat et al. | Jul 2005 | B2 |
6942641 | Seddon | Sep 2005 | B2 |
6942694 | Liddicoat et al. | Sep 2005 | B2 |
6951571 | Srivastava | Oct 2005 | B1 |
6964684 | Ortiz et al. | Nov 2005 | B2 |
6974476 | McGuckin, Jr. et al. | Dec 2005 | B2 |
6986775 | Morales et al. | Jan 2006 | B2 |
7007698 | Thornton | Mar 2006 | B2 |
7041120 | Li et al. | May 2006 | B2 |
7063722 | Marquez | Jun 2006 | B2 |
7081131 | Thornton | Jul 2006 | B2 |
7087064 | Hyde | Aug 2006 | B1 |
7112219 | Vidlund et al. | Sep 2006 | B2 |
7160322 | Gabbay | Jan 2007 | B2 |
7166127 | Spence et al. | Jan 2007 | B2 |
7192442 | Solem et al. | Mar 2007 | B2 |
7247134 | Vidlund et al. | Jul 2007 | B2 |
7297150 | Cartledge et al. | Nov 2007 | B2 |
7323004 | Parihar | Jan 2008 | B2 |
7329278 | Seguin et al. | Feb 2008 | B2 |
7329280 | Bolling et al. | Feb 2008 | B2 |
7335213 | Hyde et al. | Feb 2008 | B1 |
7357815 | Shaoulian et al. | Apr 2008 | B2 |
7361190 | Shaoulian et al. | Apr 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7455690 | Cartledge et al. | Nov 2008 | B2 |
7482936 | Bolling | Jan 2009 | B2 |
7485142 | Milo | Feb 2009 | B2 |
7507252 | Lashinski et al. | Mar 2009 | B2 |
7527646 | Rahdert et al. | May 2009 | B2 |
7534204 | Starksen et al. | May 2009 | B2 |
7556647 | Drews et al. | Jul 2009 | B2 |
7611534 | Kapadia et al. | Nov 2009 | B2 |
7637946 | Solem et al. | Dec 2009 | B2 |
7655040 | Douk et al. | Feb 2010 | B2 |
7674222 | Nikolic et al. | Mar 2010 | B2 |
7691144 | Chang et al. | Apr 2010 | B2 |
7695510 | Bloom et al. | Apr 2010 | B2 |
7722667 | Buchanan | May 2010 | B1 |
7731649 | Ferrazzi | Jun 2010 | B2 |
7740638 | Hyde | Jun 2010 | B2 |
D627245 | Corn et al. | Nov 2010 | S |
7850709 | Cummins et al. | Dec 2010 | B2 |
7860555 | Saadat | Dec 2010 | B2 |
7887582 | Mathis et al. | Feb 2011 | B2 |
7896913 | Damm et al. | Mar 2011 | B2 |
7914576 | Navia et al. | Mar 2011 | B2 |
7914577 | Cox | Mar 2011 | B2 |
7927371 | Navia et al. | Apr 2011 | B2 |
7935145 | Alfieri et al. | May 2011 | B2 |
7959673 | Carpentier et al. | Jun 2011 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
7988725 | Gross et al. | Aug 2011 | B2 |
7993395 | Vanerman et al. | Aug 2011 | B2 |
8012202 | Alameddine | Sep 2011 | B2 |
8016877 | Seguin et al. | Sep 2011 | B2 |
8052751 | Aklog et al. | Nov 2011 | B2 |
8128641 | Wardle | Mar 2012 | B2 |
8142494 | Rahdert et al. | Mar 2012 | B2 |
8142496 | Berreklouw | Mar 2012 | B2 |
8157853 | Laske et al. | Apr 2012 | B2 |
8163013 | Machold et al. | Apr 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8187207 | Machold et al. | May 2012 | B2 |
8187324 | Webler et al. | May 2012 | B2 |
8211171 | Kim et al. | Jul 2012 | B2 |
8226707 | White | Jul 2012 | B2 |
8277502 | Miller et al. | Oct 2012 | B2 |
8287555 | Starksen et al. | Oct 2012 | B2 |
8287591 | Keidar et al. | Oct 2012 | B2 |
8333777 | Schaller et al. | Dec 2012 | B2 |
8349002 | Milo | Jan 2013 | B2 |
8357195 | Kuehn | Jan 2013 | B2 |
8366766 | Berreklouw | Feb 2013 | B2 |
8382653 | Dubi et al. | Feb 2013 | B2 |
8430926 | Kirson | Apr 2013 | B2 |
8449604 | Moaddeb et al. | May 2013 | B2 |
8454683 | Rafiee et al. | Jun 2013 | B2 |
8480733 | Navia et al. | Jul 2013 | B2 |
8512403 | Navia et al. | Aug 2013 | B2 |
8551161 | Dolan | Oct 2013 | B2 |
8551162 | Fogarty et al. | Oct 2013 | B2 |
8560009 | Etemad | Oct 2013 | B2 |
8579964 | Lane et al. | Nov 2013 | B2 |
8603159 | Seguin et al. | Dec 2013 | B2 |
8608797 | Gross et al. | Dec 2013 | B2 |
8668713 | Horan et al. | Mar 2014 | B2 |
8673001 | Cartledge et al. | Mar 2014 | B2 |
8685080 | White | Apr 2014 | B2 |
8690858 | Machold et al. | Apr 2014 | B2 |
8690939 | Miller et al. | Apr 2014 | B2 |
8715342 | Zipory et al. | May 2014 | B2 |
8721681 | Ruff et al. | May 2014 | B2 |
8721718 | Kassab | May 2014 | B2 |
8758372 | Cartledge et al. | Jun 2014 | B2 |
8778021 | Cartledge | Jul 2014 | B2 |
8784482 | Rahdert et al. | Jul 2014 | B2 |
8808371 | Cartledge | Aug 2014 | B2 |
8858622 | Machold et al. | Oct 2014 | B2 |
8864823 | Cartledge et al. | Oct 2014 | B2 |
8882830 | Cartledge et al. | Nov 2014 | B2 |
8906046 | Anderson | Dec 2014 | B2 |
8926696 | Cabiri et al. | Jan 2015 | B2 |
8940042 | Miller et al. | Jan 2015 | B2 |
8945210 | Cartledge et al. | Feb 2015 | B2 |
8956407 | Macoviak et al. | Feb 2015 | B2 |
8979923 | Spence et al. | Mar 2015 | B2 |
8979925 | Chang et al. | Mar 2015 | B2 |
8992604 | Gross et al. | Mar 2015 | B2 |
8998979 | Seguin et al. | Apr 2015 | B2 |
9005272 | White | Apr 2015 | B2 |
9011520 | Miller et al. | Apr 2015 | B2 |
9023065 | Bolduc et al. | May 2015 | B2 |
9040092 | Edelman et al. | May 2015 | B2 |
9044221 | Zentgraf et al. | Jun 2015 | B2 |
9084677 | Cartledge | Jul 2015 | B2 |
9095277 | House et al. | Aug 2015 | B2 |
9101338 | Hindrichs et al. | Aug 2015 | B2 |
9107749 | Bobo et al. | Aug 2015 | B2 |
9107750 | Cartledge et al. | Aug 2015 | B2 |
9119718 | Keranen | Sep 2015 | B2 |
9138315 | Straubinger et al. | Sep 2015 | B2 |
9180005 | Lashinski et al. | Nov 2015 | B1 |
9192471 | Bolling | Nov 2015 | B2 |
9192472 | Gross et al. | Nov 2015 | B2 |
9198755 | Shaolian et al. | Dec 2015 | B2 |
9204956 | Chanduszko et al. | Dec 2015 | B2 |
9204964 | Dahlgren et al. | Dec 2015 | B2 |
9265608 | Miller et al. | Feb 2016 | B2 |
9301756 | Wardle | Apr 2016 | B2 |
9301860 | White | Apr 2016 | B2 |
9314336 | Furnish et al. | Apr 2016 | B2 |
9326859 | Cartledge et al. | May 2016 | B2 |
9339379 | Quadri et al. | May 2016 | B2 |
9351830 | Gross et al. | May 2016 | B2 |
RE46126 | Kirson | Aug 2016 | E |
RE46127 | Kirson | Aug 2016 | E |
9421099 | Dolan | Aug 2016 | B2 |
9427215 | Cartledge et al. | Aug 2016 | B2 |
9439763 | Geist et al. | Sep 2016 | B2 |
9474606 | Zipory et al. | Oct 2016 | B2 |
9492276 | Lee et al. | Nov 2016 | B2 |
9504572 | Mauch et al. | Nov 2016 | B2 |
9566178 | Cartledge et al. | Feb 2017 | B2 |
9585747 | Quadri et al. | Mar 2017 | B2 |
9592122 | Zipory et al. | Mar 2017 | B2 |
9597184 | Machold et al. | Mar 2017 | B2 |
9610156 | Lashinski | Apr 2017 | B2 |
9616197 | Serina et al. | Apr 2017 | B2 |
9713530 | Cabiri et al. | Jul 2017 | B2 |
9730790 | Quadri et al. | Aug 2017 | B2 |
9744038 | Dahlgren et al. | Aug 2017 | B2 |
9775709 | Miller et al. | Oct 2017 | B2 |
9788941 | Hacohen | Oct 2017 | B2 |
9801714 | White | Oct 2017 | B2 |
9827093 | Cartledge et al. | Nov 2017 | B2 |
9848983 | Lashinski et al. | Dec 2017 | B2 |
9861475 | Machold et al. | Jan 2018 | B2 |
9872769 | Gross et al. | Jan 2018 | B2 |
9883943 | Gross et al. | Feb 2018 | B2 |
9974653 | Gross et al. | May 2018 | B2 |
20010044637 | Jacobs et al. | Nov 2001 | A1 |
20020002401 | McGuckin, Jr. et al. | Jan 2002 | A1 |
20020042621 | Liddicoat et al. | Apr 2002 | A1 |
20020072710 | Stewart et al. | Jun 2002 | A1 |
20020151961 | Lashinski et al. | Oct 2002 | A1 |
20020161377 | Rabkin | Oct 2002 | A1 |
20020173841 | Ortiz et al. | Nov 2002 | A1 |
20020183837 | Streeter et al. | Dec 2002 | A1 |
20030040793 | Marquez | Feb 2003 | A1 |
20030050693 | Quijano et al. | Mar 2003 | A1 |
20030083742 | Spence et al. | May 2003 | A1 |
20030093148 | Bolling et al. | May 2003 | A1 |
20030158570 | Ferrazzi | Aug 2003 | A1 |
20030199974 | Lee et al. | Oct 2003 | A1 |
20030199975 | Gabbay | Oct 2003 | A1 |
20030199987 | Berg et al. | Oct 2003 | A1 |
20030212453 | Mathis et al. | Nov 2003 | A1 |
20030225420 | Wardle | Dec 2003 | A1 |
20030233142 | Morales et al. | Dec 2003 | A1 |
20040010275 | Jacobs et al. | Jan 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040067544 | Vogel et al. | Apr 2004 | A1 |
20040092965 | Parihar | May 2004 | A1 |
20040122516 | Fogarty et al. | Jun 2004 | A1 |
20040127982 | Machold et al. | Jul 2004 | A1 |
20040133274 | Webler et al. | Jul 2004 | A1 |
20040148019 | Vidlund et al. | Jul 2004 | A1 |
20040148020 | Vidlund et al. | Jul 2004 | A1 |
20040148021 | Cartledge et al. | Jul 2004 | A1 |
20040167620 | Ortiz et al. | Aug 2004 | A1 |
20040172063 | Li et al. | Sep 2004 | A1 |
20040186565 | Schreck | Sep 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040193191 | Starksen et al. | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040236419 | Milo | Nov 2004 | A1 |
20040243104 | Seddon | Dec 2004 | A1 |
20040243227 | Starksen et al. | Dec 2004 | A1 |
20040243230 | Navia et al. | Dec 2004 | A1 |
20040249400 | Vargas et al. | Dec 2004 | A1 |
20040249453 | Cartledge et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20050004665 | Aklog | Jan 2005 | A1 |
20050004668 | Aklog et al. | Jan 2005 | A1 |
20050038508 | Gabbay | Feb 2005 | A1 |
20050049692 | Numamoto et al. | Mar 2005 | A1 |
20050075713 | Bianucci et al. | Apr 2005 | A1 |
20050080454 | Drews et al. | Apr 2005 | A1 |
20050119734 | Spence et al. | Jun 2005 | A1 |
20050131533 | Alfieri et al. | Jun 2005 | A1 |
20050137701 | Salahieh et al. | Jun 2005 | A1 |
20050177180 | Kaganov et al. | Aug 2005 | A1 |
20050182290 | Lau et al. | Aug 2005 | A1 |
20050182486 | Gabbay | Aug 2005 | A1 |
20050192629 | Saadat et al. | Sep 2005 | A1 |
20050197696 | Gomez Duran | Sep 2005 | A1 |
20050234508 | Cummins et al. | Oct 2005 | A1 |
20050250986 | Rothe et al. | Nov 2005 | A1 |
20050267560 | Bates | Dec 2005 | A1 |
20050267572 | Schoon et al. | Dec 2005 | A1 |
20050288776 | Shaoulian et al. | Dec 2005 | A1 |
20050288783 | Shaoulian et al. | Dec 2005 | A1 |
20060015178 | Moaddeb et al. | Jan 2006 | A1 |
20060020332 | Lashinski et al. | Jan 2006 | A1 |
20060025854 | Lashinski et al. | Feb 2006 | A1 |
20060025855 | Lashinski et al. | Feb 2006 | A1 |
20060025858 | Alameddine | Feb 2006 | A1 |
20060069429 | Spence et al. | Mar 2006 | A1 |
20060100699 | Vidlund et al. | May 2006 | A1 |
20060106305 | Lau | May 2006 | A1 |
20060106456 | Machold et al. | May 2006 | A9 |
20060129235 | Seguin et al. | Jun 2006 | A1 |
20060149349 | Garbe | Jul 2006 | A1 |
20060149368 | Spence | Jul 2006 | A1 |
20060178733 | Pinchuk et al. | Aug 2006 | A1 |
20060184240 | Jimenez et al. | Aug 2006 | A1 |
20060184241 | Marquez | Aug 2006 | A1 |
20060195012 | Mortier et al. | Aug 2006 | A1 |
20060206203 | Yang et al. | Sep 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060241746 | Shaoulian et al. | Oct 2006 | A1 |
20060241747 | Shaoulian et al. | Oct 2006 | A1 |
20060241748 | Lee et al. | Oct 2006 | A1 |
20060282161 | Huynh et al. | Dec 2006 | A1 |
20060282162 | Nguyen et al. | Dec 2006 | A1 |
20070005129 | Damm et al. | Jan 2007 | A1 |
20070016287 | Cartledge et al. | Jan 2007 | A1 |
20070016288 | Gurskis et al. | Jan 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070027536 | Mihaljevic et al. | Feb 2007 | A1 |
20070049942 | Hindrichs et al. | Mar 2007 | A1 |
20070050019 | Hyde | Mar 2007 | A1 |
20070055368 | Rhee et al. | Mar 2007 | A1 |
20070083259 | Bloom et al. | Apr 2007 | A1 |
20070093890 | Eliasen et al. | Apr 2007 | A1 |
20070112423 | Chu | May 2007 | A1 |
20070112425 | Schaller et al. | May 2007 | A1 |
20070142907 | Moaddeb et al. | Jun 2007 | A1 |
20070156233 | Kapadia et al. | Jul 2007 | A1 |
20070161846 | Nikolic et al. | Jul 2007 | A1 |
20070239272 | Navia et al. | Oct 2007 | A1 |
20070244553 | Rafiee et al. | Oct 2007 | A1 |
20070244554 | Rafiee et al. | Oct 2007 | A1 |
20070244555 | Rafiee et al. | Oct 2007 | A1 |
20070244556 | Rafiee et al. | Oct 2007 | A1 |
20070250161 | Dolan | Oct 2007 | A1 |
20070265701 | Gurskis et al. | Nov 2007 | A1 |
20070276478 | Marmureanu et al. | Nov 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20070293942 | Mirzaee | Dec 2007 | A1 |
20070299543 | Cartledge et al. | Dec 2007 | A1 |
20080027483 | Cartledge et al. | Jan 2008 | A1 |
20080067713 | Bordener | Mar 2008 | A1 |
20080071364 | Kaye et al. | Mar 2008 | A1 |
20080077235 | Kirson | Mar 2008 | A1 |
20080177380 | Starksen et al. | Jul 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080262609 | Gross et al. | Oct 2008 | A1 |
20080288060 | Kaye et al. | Nov 2008 | A1 |
20090082857 | Lashinski et al. | Mar 2009 | A1 |
20090087414 | Edelman et al. | Apr 2009 | A1 |
20090149872 | Gross et al. | Jun 2009 | A1 |
20090177276 | Carpentier et al. | Jul 2009 | A1 |
20090182419 | Bolling | Jul 2009 | A1 |
20090198316 | Laske et al. | Aug 2009 | A1 |
20090259304 | O'Beirne | Oct 2009 | A1 |
20090264996 | Vanerman et al. | Oct 2009 | A1 |
20090276040 | Rowe et al. | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090287304 | Dahlgren et al. | Nov 2009 | A1 |
20090306622 | Machold et al. | Dec 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100049315 | Kirson | Feb 2010 | A1 |
20100087855 | Leung et al. | Apr 2010 | A1 |
20100100174 | Gurskis | Apr 2010 | A1 |
20100121433 | Bolling et al. | May 2010 | A1 |
20100152838 | Kang et al. | Jun 2010 | A1 |
20100152840 | Seguin et al. | Jun 2010 | A1 |
20100152845 | Bloom et al. | Jun 2010 | A1 |
20100185229 | Horan et al. | Jul 2010 | A1 |
20100249920 | Bolling et al. | Sep 2010 | A1 |
20100280604 | Zipory et al. | Nov 2010 | A1 |
20100298929 | Thornton et al. | Nov 2010 | A1 |
20110022166 | Dahlgren et al. | Jan 2011 | A1 |
20110060407 | Ketai et al. | Mar 2011 | A1 |
20110066224 | White | Mar 2011 | A1 |
20110066236 | Khalapyan | Mar 2011 | A1 |
20110106245 | Miller et al. | May 2011 | A1 |
20110106247 | Miller et al. | May 2011 | A1 |
20110166649 | Gross et al. | Jul 2011 | A1 |
20110172760 | Anderson | Jul 2011 | A1 |
20110190879 | Bobo et al. | Aug 2011 | A1 |
20110202127 | Mauch et al. | Aug 2011 | A1 |
20110219603 | White | Sep 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110230956 | White | Sep 2011 | A1 |
20110230961 | Langer et al. | Sep 2011 | A1 |
20110288632 | White | Nov 2011 | A1 |
20110319989 | Lane et al. | Dec 2011 | A1 |
20120022640 | Gross et al. | Jan 2012 | A1 |
20120027116 | Etemad | Feb 2012 | A1 |
20120053680 | Bolling et al. | Mar 2012 | A1 |
20120109288 | Bolling | May 2012 | A1 |
20120109289 | Bolling | May 2012 | A1 |
20120136436 | Cabiri | May 2012 | A1 |
20120197388 | Khairkhahan et al. | Aug 2012 | A1 |
20120203330 | Cartledge et al. | Aug 2012 | A1 |
20120209379 | Shaolian et al. | Aug 2012 | A1 |
20120215303 | Quadri et al. | Aug 2012 | A1 |
20120283757 | Miller et al. | Nov 2012 | A1 |
20120308610 | Edelman et al. | Dec 2012 | A1 |
20130006295 | Chanduszko et al. | Jan 2013 | A1 |
20130030523 | Padala et al. | Jan 2013 | A1 |
20130046373 | Cartledge et al. | Feb 2013 | A1 |
20130123910 | Cartledge et al. | May 2013 | A1 |
20130123913 | Kuehn | May 2013 | A1 |
20130138207 | Quadri et al. | May 2013 | A1 |
20130144380 | Quadri et al. | Jun 2013 | A1 |
20130177600 | Edelman et al. | Jul 2013 | A1 |
20130226289 | Shaolian et al. | Aug 2013 | A1 |
20130289710 | Leedle | Oct 2013 | A1 |
20130289719 | Dobrilovic | Oct 2013 | A1 |
20130296999 | Burriesci et al. | Nov 2013 | A1 |
20130325118 | Cartledge | Dec 2013 | A1 |
20140018913 | Cartledge et al. | Jan 2014 | A1 |
20140039612 | Dolan | Feb 2014 | A1 |
20140142695 | Gross et al. | May 2014 | A1 |
20140163690 | White | Jun 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140277427 | Ratz et al. | Sep 2014 | A1 |
20140277563 | White | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140309731 | Quadri et al. | Oct 2014 | A1 |
20140336756 | Lee et al. | Nov 2014 | A1 |
20150081014 | Gross et al. | Mar 2015 | A1 |
20150112432 | Reich et al. | Apr 2015 | A1 |
20150127096 | Rowe et al. | May 2015 | A1 |
20150142105 | Bolling et al. | May 2015 | A1 |
20150148896 | Karapetian et al. | May 2015 | A1 |
20150157459 | Macoviak et al. | Jun 2015 | A1 |
20150250461 | Berreklouw | Sep 2015 | A1 |
20160008130 | Hasin | Jan 2016 | A1 |
20160015513 | Lashinski et al. | Jan 2016 | A1 |
20160015514 | Lashinski et al. | Jan 2016 | A1 |
20160015515 | Lashinski et al. | Jan 2016 | A1 |
20160038285 | Glenn et al. | Feb 2016 | A1 |
20160095704 | Whitman | Apr 2016 | A1 |
20160120645 | Alon | May 2016 | A1 |
20160128829 | Oba et al. | May 2016 | A1 |
20160235526 | Lashinski et al. | Aug 2016 | A1 |
20160256276 | Yaron | Sep 2016 | A1 |
20160317304 | Spence et al. | Nov 2016 | A1 |
20160324638 | Dolan | Nov 2016 | A1 |
20160346084 | Taylor et al. | Dec 2016 | A1 |
20160361168 | Gross et al. | Dec 2016 | A1 |
20160361169 | Gross et al. | Dec 2016 | A1 |
20170000609 | Gross et al. | Jan 2017 | A1 |
20170035562 | Quadri et al. | Feb 2017 | A1 |
20170035564 | Ryan et al. | Feb 2017 | A1 |
20170049570 | O'Beimne et al. | Feb 2017 | A1 |
20170086974 | Lashinski et al. | Mar 2017 | A1 |
20170143488 | Lashinski et al. | May 2017 | A1 |
20170156860 | Lashinski et al. | Jun 2017 | A1 |
20170209253 | Lashinski et al. | Jul 2017 | A1 |
20170231759 | Geist et al. | Aug 2017 | A1 |
20170348098 | Rowe et al. | Dec 2017 | A1 |
20170360549 | Lashinski et al. | Dec 2017 | A1 |
20170367825 | Cabiri et al. | Dec 2017 | A1 |
20180014934 | Miller et al. | Jan 2018 | A1 |
20180028311 | Hacohen | Feb 2018 | A1 |
20180085217 | Lashinski et al. | Mar 2018 | A1 |
20180228610 | Lashinski et al. | Aug 2018 | A1 |
20180263776 | Gross et al. | Sep 2018 | A1 |
20180263777 | Gross et al. | Sep 2018 | A1 |
Number | Date | Country |
---|---|---|
0624080 | Dec 2001 | EP |
1872743 | Jan 2008 | EP |
2047824 | May 2012 | EP |
2656816 | Oct 2013 | EP |
2008538937 | Nov 2008 | JP |
2010284536 | Dec 2010 | JP |
9009153 | Aug 1990 | WO |
9315690 | Aug 1993 | WO |
9712565 | Apr 1997 | WO |
9720524 | Jun 1997 | WO |
9824386 | Jun 1998 | WO |
9929269 | Jun 1999 | WO |
9949816 | Oct 1999 | WO |
0007521 | Feb 2000 | WO |
0018333 | Apr 2000 | WO |
0044311 | Aug 2000 | WO |
0062715 | Oct 2000 | WO |
0189440 | Nov 2001 | WO |
02034121 | May 2002 | WO |
02094132 | Nov 2002 | WO |
03017874 | Mar 2003 | WO |
03053289 | Jul 2003 | WO |
03080150 | Oct 2003 | WO |
03015670 | Dec 2003 | WO |
03105730 | Dec 2003 | WO |
04014282 | Feb 2004 | WO |
04019816 | Mar 2004 | WO |
04019826 | Mar 2004 | WO |
04030569 | Apr 2004 | WO |
04031717 | Apr 2004 | WO |
04032717 | Apr 2004 | WO |
04082538 | Sep 2004 | WO |
04103223 | Dec 2004 | WO |
04112657 | Dec 2004 | WO |
05002424 | Jan 2005 | WO |
05007037 | Jan 2005 | WO |
05046488 | May 2005 | WO |
05087139 | Sep 2005 | WO |
06011275 | Feb 2006 | WO |
06052687 | May 2006 | WO |
06086135 | Aug 2006 | WO |
06086434 | Aug 2006 | WO |
06105084 | Oct 2006 | WO |
06116129 | Nov 2006 | WO |
06116357 | Nov 2006 | WO |
07021834 | Feb 2007 | WO |
07103562 | Sep 2007 | WO |
07136783 | Nov 2007 | WO |
0815257 | Feb 2008 | WO |
08068756 | Jun 2008 | WO |
08088716 | Jul 2008 | WO |
09120764 | Oct 2009 | WO |
09126629 | Oct 2009 | WO |
09140268 | Nov 2009 | WO |
10011699 | Jan 2010 | WO |
10048151 | Apr 2010 | WO |
12027116 | Mar 2012 | WO |
12167095 | Dec 2012 | WO |
13088327 | Jun 2013 | WO |
14043527 | Mar 2014 | WO |
2014043527 | Mar 2014 | WO |
2014210263 | Dec 2014 | WO |
2015057407 | Apr 2015 | WO |
1577599 | May 2015 | WO |
2015148241 | Oct 2015 | WO |
Entry |
---|
B.Braun Medical Inc., “Pulmonary Embolism:IVC Filters.” Retrieved from the Internet: http://www.bbraunusa.com/pe/be05a.html, 2004, 2 pages. |
Bonow et al; “ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease,” Journal of American College of Cardiology, vol. 48(3): pp. e1-e148, 2006. |
Boston Scientific, “Device Details.” Retrieved from the Internet: http://bostonscientific.com/med_specialty/deviceDetail.jsp, 1 page, [retrieved on Aug. 31, 2006.]. |
Braunberger et al; “Very Long-Term Results (More Than 20 years) of Valve Repair with Carpentier's Techniques in Nonrheumatic Mitral Valve Insufficiency,” Circulation, vol. 104, pp. I18-I11, 2001. |
Braunwald et al; “Conservative Management of Tricuspid Regurgitation in Patients Undergoing Mitral Valve Replacement,” Circulation, vols. XXXV and XXXVI: pp. 163-169, 1967. |
Carpentier et al; “Surgical Management of Acquired Tricuspid Valve Disease,” Journal of Thoracic and Cardiovascular Surgery, vol. 67(1): pp. 53-65, 1974. |
Center for Devices and Radiological Health, U.S. Department of Health and Human Services Food and Drug Administration “Guidance for Annuloplasty Rings 510(k) Submissions; Final Guidance for industry and FDA Staff,” pp. 1-15, 2001. |
Cosgrove et al; “Mitral Valvuloplasty,” Curro. Probl. Cardiology, pp. 349-405, 1989. |
Dreyfus et al; “Secondary Tricuspid Regurgitation or Dilatation: Which Should Be the Criteria for Surgical Repair?,” Annual Thoracic Surgery, vol. 79, pp. 127-132, 2005. |
Google Images, Recurved Hooks. Retrieved from the Internet: www.implementology.org.pf and personal .cityu.edu.hk, 1 page, [Retrieved on Dec. 14, 2006]. |
Leung et al; “Barbed, Bi-directional Surgical Sutures: In Vivo Strength and Histopathology Evaluations,” Society for Biomaterials 28th Annual Meeting Transactions, #724, 1 page, 2003. |
Magovern et al; “Sutureless Artificial Heart Valves,” Circulation, vol. 27, pp. 784-788, 1963. |
McCarthy et al; “Tricuspid Valve Repair: Durability and Risk Factors for Failure,” Journal of Thoracic and Cardiovascular Surgery, vol. 127, pp. 674-685, 2004. |
Nath et al; “Impact of Regurgitation on Long-Term Survival,” Journal of American College of Cardiology, vol. 43, (3): pp. 405-409, 2004. |
Navia et al; “Surgical Management of Secondary Tricuspid Valve Regurgitation: Annulus, Commissure, or Leaflet Procedure?,” Abstract presented at American Association for Thoracic Surgery Annual Meeting, 2009. |
Rogers et al; “The Tricuspid Valve: Current Perspective and Evolving Management of Tricuspid Regurgitation,” Circulation, vol. 199, pp. 2718-2725, 2009. |
Sagie et al; “Determinants of Functional Tricuspid Regurgitation in Incomplete Tricuspid Valve Closure: Doppler Color Flow Study of 109 Patients,” Journal of American College of Cardiology, vol. 24, pp. 446-453, 1994. |
Savage et al; “Use of Mitral Valve Repair: Analysis of Contemporary United States Experience Reported to the Society of Thoracic Surgeons National Cardiac Database,” Annual Thoracic Surgery, vol. 75, pp. 820-825, 2003. |
Shiran et al; Tricuspid Regurgitation in Mitral Valve Disease, Journal of the American College of Cardiology, vol. 53(5), pp. 401-408, 2009. |
Song et al; “Factors Associated with Development of Late Significant Tricuspid Regurgitation after Successful Left-Sided Valve Surgery,” Heart, vol. 95, pp. 931-936, 2009. |
Tang et al; “Tricuspid Valve Repair with an Annuloplasty Ring results in Improved Long-Term Outcomes,” Circulation, vol. 114, pp. 1577-1581, 2006. |
Thompson “Percutaneous Heart Valve Technology: The Mitral Challenge,” Medtech Insight, vol. 11(2): pp. 38-52, 2009. |
Zlotnick et al; “A Perfectly Functioning Magovern-Cromie Sutureless Prosthetic Aortic Valve 42 Years After Implantation,” Circulation, vol. 117: pp. e1-e2, 2008. |
International Search Report and Written Opinion: Application No. PCT/US2013/059751; 8 pages, dated Dec. 11, 2013. |
Extended European Search Report dated Jun. 13, 2016 in European Patent Application No. 13837432.7. |
International Search Report and Written Opinion dated May 26, 2017 for PCT/US2017/016284. |
International Search Report dated Oct. 8, 2015 for PCT/US2015/040622. |
International Search Report dated Jul. 1, 2008 for PCT/US2008/050224. |
International Search Report dated Jul. 13, 2010 for PCT/US2010/027943. |
International Search Report dated Sep. 22, 2011 for PCT/US2011/039022. |
International Search Report dated Dec. 7, 2011 for PCT/US2011/047345. |
International Search Report dated Jul. 21, 2014 for PCT/US2014/026333. |
International Search Report dated May 5, 2016 for PCT/US2016/017866. |
International Search Report dated Apr. 19, 2017 for PCT/US16/062107. |
Number | Date | Country | |
---|---|---|---|
20230077976 A1 | Mar 2023 | US |
Number | Date | Country | |
---|---|---|---|
62291347 | Feb 2016 | US | |
61700989 | Sep 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17081128 | Oct 2020 | US |
Child | 17991790 | US | |
Parent | 15423374 | Feb 2017 | US |
Child | 17081128 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14427909 | US | |
Child | 15423374 | US |